Here it is: "we decided to downgrade ONTY stock from strong short sell recommendation to single best short idea for the next 2 years. As expected, stimuvax showed huge side effects and the trial is now halted. We believe PX-866 is the next trial to be halted for lack of effectiveness. We also belive more stock dilution is coming for ONTY. ONTY is clearly the worst biotech stock we cover."
This is just out from our research department. So you see, I just provide high quality, unbiased information. Thank you